ZA200900264B - Polymorphic crystal form of a indan-2-ylamino-hydroxyethyl-quinolinone maleate derivative as beta-adrenoceptor agonist - Google Patents

Polymorphic crystal form of a indan-2-ylamino-hydroxyethyl-quinolinone maleate derivative as beta-adrenoceptor agonist

Info

Publication number
ZA200900264B
ZA200900264B ZA200900264A ZA200900264A ZA200900264B ZA 200900264 B ZA200900264 B ZA 200900264B ZA 200900264 A ZA200900264 A ZA 200900264A ZA 200900264 A ZA200900264 A ZA 200900264A ZA 200900264 B ZA200900264 B ZA 200900264B
Authority
ZA
South Africa
Prior art keywords
quinolinone
indan
ylamino
hydroxyethyl
beta
Prior art date
Application number
ZA200900264A
Other languages
English (en)
Inventor
Olivier Lohse
Stephanie Monnier
Guido Jordine
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37714644&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA200900264(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of ZA200900264B publication Critical patent/ZA200900264B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/24—Oxygen atoms attached in position 8
    • C07D215/26—Alcohols; Ethers thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Quinoline Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
ZA200900264A 2006-08-31 2009-01-13 Polymorphic crystal form of a indan-2-ylamino-hydroxyethyl-quinolinone maleate derivative as beta-adrenoceptor agonist ZA200900264B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06119895A EP1914227A1 (de) 2006-08-31 2006-08-31 Kristalline Polymorphe Form von Indan-2-ylamino-hydroxyethyl-quinolinon-maleat Derivat als beta-Adrenorezeptor-Agonist

Publications (1)

Publication Number Publication Date
ZA200900264B true ZA200900264B (en) 2010-05-26

Family

ID=37714644

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200900264A ZA200900264B (en) 2006-08-31 2009-01-13 Polymorphic crystal form of a indan-2-ylamino-hydroxyethyl-quinolinone maleate derivative as beta-adrenoceptor agonist

Country Status (21)

Country Link
US (1) US20100010039A1 (de)
EP (2) EP1914227A1 (de)
JP (1) JP2010501631A (de)
KR (1) KR20090049615A (de)
CN (1) CN101511794A (de)
AR (1) AR063698A1 (de)
AU (1) AU2007291270A1 (de)
BR (1) BRPI0716383A2 (de)
CA (1) CA2659144A1 (de)
CL (1) CL2007002525A1 (de)
GT (1) GT200900037A (de)
IL (1) IL196805A0 (de)
MA (1) MA30763B1 (de)
MX (1) MX2009002301A (de)
NO (1) NO20091234L (de)
PE (1) PE20080923A1 (de)
RU (1) RU2009111389A (de)
TN (1) TN2009000056A1 (de)
TW (1) TW200817333A (de)
WO (1) WO2008025816A1 (de)
ZA (1) ZA200900264B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2481738A1 (de) * 2009-09-25 2012-08-01 Kyorin Pharmaceutical Co., Ltd. Maleinsäuresalz und kristall daraus
EP3205646A3 (de) 2013-03-27 2017-10-04 Laboratorios Lesvi, S.L. Zwischenprodukte zur herstellung von (r)-5-[2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-(1h)-chinolin-2-on (indacaterol)
CN103830195A (zh) * 2014-03-11 2014-06-04 熊妲妮 一种茚达特罗片及其制备方法
CN103830193A (zh) * 2014-03-11 2014-06-04 熊妲妮 茚达特罗片制剂及其制备方法
EP3347345B1 (de) 2015-09-29 2019-07-31 Inke, S.A. Gemischtes solvat von (r)-5-[2-(5,6-diethylindan-2-ylamino)-1-hydroxyethyl]-8-hydroxy-1h-chinolin-2-on-l-tartrat

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9913083D0 (en) * 1999-06-04 1999-08-04 Novartis Ag Organic compounds
GB0413960D0 (en) * 2004-06-22 2004-07-28 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
CN101511794A (zh) 2009-08-19
AU2007291270A1 (en) 2008-03-06
US20100010039A1 (en) 2010-01-14
RU2009111389A (ru) 2010-10-10
WO2008025816A1 (en) 2008-03-06
CL2007002525A1 (es) 2008-07-11
EP1914227A1 (de) 2008-04-23
BRPI0716383A2 (pt) 2013-09-24
IL196805A0 (en) 2009-11-18
TN2009000056A1 (en) 2010-08-19
NO20091234L (no) 2009-03-30
PE20080923A1 (es) 2008-07-11
KR20090049615A (ko) 2009-05-18
GT200900037A (es) 2010-03-11
MA30763B1 (fr) 2009-10-01
EP2066639A1 (de) 2009-06-10
TW200817333A (en) 2008-04-16
MX2009002301A (es) 2009-03-20
AR063698A1 (es) 2009-02-11
CA2659144A1 (en) 2008-03-06
JP2010501631A (ja) 2010-01-21

Similar Documents

Publication Publication Date Title
IL193638A0 (en) Amine derivatives
TWI561510B (en) Intermediate compounds for preparing zaocyclic amides
IL200328A0 (en) 3-cyano-4-(4-phenyl-piperidin-1-yl)-pyridin-2-one derivatives
EP2098517A4 (de) Neues phenylisoxazol-3-olderivat
EP2816024B8 (de) Chirale Amine
SI2155200T1 (sl) Kristalinična oblika kabamoil-cikloheksanskega derivata
EP2009005A4 (de) Azolcarbonsäureamidderivat
ZA200809800B (en) 2-Thioxanthine derivatives acting as Mpo-inhibitors
HRP20140047T1 (en) Cycloptopyl amide derivatives
IL195007A0 (en) Thiazole derivatives
IL195296A0 (en) Heterocyclic type cinnamide derivative
AP2007004282A0 (en) Derivatives of A 1-phenyltriazole as antiparasiticagents
HK1124068A1 (en) 2-arylindole derivatives as mpges-1 inhibitors
ZA200903614B (en) New crystalline forms
IL196805A0 (en) Polymorphic crystal form of a indan-2-ylamino-hydroxyethyl-quinolinone maleate derivative as beta-adrenoceptor agonist
GB0612508D0 (en) Crystalline duloxetine hydrochloride
GB0622472D0 (en) Novel heterocyclic derivatives
IL237789A0 (en) Methods for using thiazole history
EP2119702A4 (de) Amidderivat
GB0700830D0 (en) Crystalline duloxetine hydrochloride
IL184395A0 (en) Novel salt form of a dopamine agonist
GB0612506D0 (en) Crystalline duloxetine hydrochloride
IL193981A0 (en) Novel heterocyclic nf-kb inhibitors
EP2096106A4 (de) Neue polyaminderivate
EP1878719A4 (de) Kristallpolymorph eines hydroxynorephedrin­deriva­thydro­chlorids